US$ 27.75
parkinson glutathione oxidative ipsc crispr CRISPR/Cas9 assisted stem cell therapy in Parkinson's disease Non-invasive CRISPR/Cas9 nanocapsules specifically edit
Description
Blood 140, 18371844

ATN-161 enhances the activity of radiation and chemotherapy and is progressing to a phase II trial for head and neck cancer [153]

Although NRPS product assembly frequently seems to display a strict correlation between the enzymatic domain sequence of the megasynthase and the position of the amino acid building blocks in the peptide product, this colinearity rule is not strictly reinforced in nature 36,37

RBM-007, an RNA aptamer designed to target fibroblast growth factor 2 (FGF2), is currently in Phase II clinical trials for treating neovascular AMD (nAMD)
